A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation

NCT02906020 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

273

Enrollment

INDUSTRY

Sponsor class

Stopped The topline results of the 52-week double-blind placebo-controlled period were analyzed. The study did not meet the primary or secondary endpoints. Based on these results, the decision was made to halt the long-term follow-up period of the study

Conditions

Parkinson's Disease

Interventions

DRUG: venglustat GZ/SAR402671
DRUG: Placebo

Sponsor

Genzyme, a Sanofi Company